Retatrutide 40mg (10 Vials / Kit)

Retatrutide 40mg delivers ten lyophilised vials of the triple GIP/GLP-1/glucagon receptor agonist for laboratories that reconstitute at high concentration or run many parallel experiments from a single kit. Every batch is independently tested for identity and purity (≥99% by HPLC) and shipped with a batch-specific certificate of analysis.

What is Retatrutide?

Retatrutide (LY3437943) is a single-molecule peptide that activates three incretin-related receptors at once: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon receptor (GCGR). It was engineered by Eli Lilly from a GIP backbone, carries a C20 fatty di-acid side chain that binds albumin, and has a half-life of roughly six days, which is why once-weekly administration was used in its clinical programme. Because the three receptors act on appetite, insulin secretion and energy expenditure through different pathways, retatrutide is often described as the first “triple agonist” and is considered the successor to the dual agonist tirzepatide.

What the research shows

• Phase 2 obesity trial (NEJM, 2023). In 338 adults with obesity, 48 weeks of retatrutide produced a mean weight reduction of up to 24.2% at the 12mg dose – the largest reported for any single agent at the time – with weight loss still trending downward at study end.
• Type 2 diabetes (Lancet, 2023). In a 36-week phase 2 study, HbA1c fell by up to 2.0 percentage points alongside weight loss of up to 17%, with a safety profile consistent with the GLP-1 class (mainly transient gastrointestinal effects).
• Liver fat. A sub-study using MRI-PDFF reported that more than 80% of participants at the higher doses achieved normalisation of liver fat at 48 weeks, prompting interest in metabolic dysfunction-associated steatotic liver disease (MASLD) research.
• Mechanistic work. Preclinical studies attribute the additional efficacy over dual agonists to glucagon-receptor-driven increases in energy expenditure and hepatic fat oxidation, layered on top of GLP-1/GIP-mediated appetite suppression.
• Phase 3. The TRIUMPH programme (obesity, obstructive sleep apnoea, knee osteoarthritis and cardiovascular outcomes) is ongoing; retatrutide is not yet approved by any regulator.

Research applications

Retatrutide is used in laboratory models of obesity and energy balance, glucose homeostasis and insulin secretion, hepatic steatosis, incretin-receptor pharmacology and cross-comparison studies against semaglutide and tirzepatide. Its multi-receptor profile also makes it a useful tool for dissecting the individual contributions of GLP-1R, GIPR and GCGR signalling in vitro.

Specifications

• Contents: 10 vials × 40mg Retatrutide
• Form: Lyophilised powder
• Molecular Formula: C221H342N46O68
• Molecular Weight: ~4731.3 g/mol
• Purity: ≥99% (HPLC), batch COA supplied
• Storage: Store lyophilised at -20°C; reconstituted solution at 2–8°C, protected from light

For laboratory research use only. Not for human or veterinary use. Retatrutide is an investigational compound and is not approved for any medical indication.